GlassScriptPhysician profile
Alisa R Wolner
NPI 1033129549
$6,972.45
in general payments reported to CMS, 2019-2025
36 companies · $1,185 in 2025
The $1,185 reported for 2025 was more than what 92% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $390 · 2020: $322 · 2021: $955 · 2022: $1,329 · 2023: $1,622 · 2024: $1,170 · 2025: $1,185.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,883 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,883.17 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coloplast Corp | $1,180.00 | 2021-2025 | Restorelle |
| Abbvie INC. | $936.14 | 2019-2025 | Liletta, Orilissa, Lo Loestrin Fe |
| Myovant Sciences INC. | $640.49 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $479.76 | 2023-2024 | Myfembree |
| Aspira Women'S Health INC | $468.55 | 2021-2025 | Ova1 |
| Mayne Pharma Commercial LLC | $313.39 | 2021-2025 | |
| Astellas Pharma US INC | $295.20 | 2019-2025 | Veozah |
| Biogen, INC. | $259.07 | 2024-2025 | Zurzuvae |
| Exeltis, USA INC. | $250.42 | 2020-2025 | Slynd |
| Pfizer INC. | $219.39 | 2020-2025 | |
| Hologic Sales and Service, LLC | $199.73 | 2019-2025 | Coolseal Generator, Aptima, Thinprep 2000 Processor |
| Bayer Healthcare Pharmaceuticals INC. | $168.99 | 2019-2025 | |
| Organon LLC | $149.88 | 2021-2025 | Nexplanon, Jada System |
| Medtronic, INC. | $143.03 | 2023-2024 | V-Loc 180, Situate |
| Minerva Surgical, INC | $141.74 | 2019-2025 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $119.28 | 2024 | (Bh4) Igt Devices Undivided |
| Millicent US INC | $98.83 | 2024-2025 | Intrarosa, Femring, Femlyv |
| Therapeuticsmd, INC. | $86.51 | 2020-2022 | |
| Vertex Pharmaceuticals Incorporated | $79.49 | 2025 | |
| Coopersurgical, INC. | $76.75 | 2019-2024 | Paragard T 380a |
| Intuitive Surgical, INC. | $71.74 | 2023 | Da Vinci Surgical System |
| Agile Therapeutics, INC. | $67.11 | 2021-2024 | Twirla |
| Channel Medsystems, INC. | $63.10 | 2025 | |
| Ascend Therapeutics US, LLC | $62.44 | 2021-2023 | |
| Avion Pharmaceuticals | $50.79 | 2020-2023 | Balcoltra |
| Smith+Nephew, INC. | $49.81 | 2021-2024 | Pico 7 |
| Daiichi Sankyo INC. | $49.08 | 2019 | |
| Shield Therapeutics INC | $47.72 | 2023-2024 | Accrufer |
| Merck Sharp & Dohme LLC | $44.15 | 2019-2021 | |
| Mylan Pharmaceuticals INC. | $41.56 | 2021 | |
| Allergan, INC. | $32.40 | 2019 | |
| Amgen INC. | $31.75 | 2019-2020 | |
| Lupin INC. | $17.02 | 2019 | |
| Amag Pharmaceuticals, INC. | $14.67 | 2019 | |
| Zyla Life Sciences, INC. | $11.26 | 2020 | |
| Covidien LP | $11.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alisa Wolner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.